Anaptysbio (ANAB) Non-Current Assets (2016 - 2026)
Anaptysbio's (ANAB) quarterly Non-Current Assets came in at $13.6 million in Q1 2026, down 76.97% YoY from $58.9 million in Q1 2025, and down 4.03% on a QoQ basis from $14.1 million in Q4 2025.
Anaptysbio (ANAB) Non-Current Assets (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Non-Current Assets data on file, last reported at $13.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 76.97% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.5 million (down 56.64% YoY) and the FY2025 annual result came in at $14.1 million, down 72.78% from the prior year.
- Non-Current Assets slipped to $13.6 million in Q1 2026, from $14.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $168.1 million in Q3 2022 to a low of $13.6 million in Q1 2026.
- A 5-year average of $72.7 million and a median of $58.9 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 1114.17% — and 2026, when it tumbled 76.97%.
- Tracing ANAB's Non-Current Assets over 5 years: stood at $163.2 million in 2022, then tumbled by 72.08% to $45.6 million in 2023, then advanced by 14.06% to $52.0 million in 2024, then tumbled by 72.78% to $14.1 million in 2025, then slipped by 4.03% to $13.6 million in 2026.
- The last three Non-Current Assets figures came in at $13.6 million (Q1 2026), $14.1 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 13.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.58 Mn |
| Dec 31, 2025 | 14.15 Mn |
| Sep 30, 2025 | 22.45 Mn |
| Jun 30, 2025 | 43.34 Mn |
| Mar 31, 2025 | 58.94 Mn |
| Dec 31, 2024 | 51.96 Mn |
| Sep 30, 2024 | 44.74 Mn |
| Jun 30, 2024 | 60.03 Mn |
| Mar 31, 2024 | 33.42 Mn |
| Dec 31, 2023 | 45.55 Mn |
| Sep 30, 2023 | 59.33 Mn |
| Jun 30, 2023 | 78.57 Mn |
| Mar 31, 2023 | 114.64 Mn |
| Dec 31, 2022 | 163.18 Mn |
| Sep 30, 2022 | 168.06 Mn |
| Jun 30, 2022 | 151.04 Mn |
| Mar 31, 2022 | 112.76 Mn |
| Dec 31, 2021 | 89.19 Mn |
| Sep 30, 2021 | 37.69 Mn |
| Jun 30, 2021 | 28.51 Mn |